quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:04·231d
SECFiling
iTeos Therapeutics Inc. logo

SEC Form EFFECT filed by iTeos Therapeutics Inc.

ITOS· iTeos Therapeutics Inc.
Health Care
Original source

Companies

  • ITOS
    iTeos Therapeutics Inc.
    Health Care

Recent analyst ratings

  • May 28UpdateWells Fargo$12.00
  • May 28UpdateWedbush$12.00
  • May 14UpdateLeerink Partners$9.00
  • May 14UpdateH.C. Wainwright-
  • May 13UpdateAnalyst-
  • Aug 13UpdateWells Fargo$31.00

Related

  • SEC227d
    SEC Form 15-12G filed by iTeos Therapeutics Inc.
  • SEC232d
    Amendment: SEC Form SCHEDULE 13D/A filed by iTeos Therapeutics Inc.
  • INSIDER237d
    Chief Operating Officer Call Matthew closing all direct ownership in the company (SEC Form 4)
  • INSIDER237d
    Chief Executive Officer Detheux Michel closing all direct ownership in the company (SEC Form 4)
  • INSIDER237d
    SEC Form 4 filed by Director Lee David K
  • INSIDER237d
    Chief Medical Officer Feltquate David closing all direct ownership in the company (SEC Form 4)
  • INSIDER237d
    Chief Scientific Officer Mcgrath Yvonne closing all direct ownership in the company (SEC Form 4)
  • INSIDER237d
    Chief Financial Officer Gall Matthew closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022